<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00302848</url>
  </required_header>
  <id_info>
    <org_study_id>ZEG 2000_1</org_study_id>
    <nct_id>NCT00302848</nct_id>
  </id_info>
  <brief_title>European Active Surveillance Study (EURAS)</brief_title>
  <official_title>The European Active Surveillance Study on OC Prescribing Practice, Benefits and Safety (EURAS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Center for Epidemiology and Health Research, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Center for Epidemiology and Health Research, Germany</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      EURAS is a multi-national, controlled, prospective, post-marketing, non-intervention cohort
      study of new users of drospirenone/ethinylestradiol (DRSP/EE),
      levonorgestrel/ethinylestradiol (LNG/EE) and other oral contraceptives (OCs) under routine
      conditions of medical practice in seven European countries. Baseline survey and semiannual,
      active follow-up are based on postal questionnaires, with validation of reported events by
      the women's treating physicians. A multifaceted 4-level follow-up procedure will be
      established to ensure low loss to follow-up rates. The objective of the study is the
      investigation of the incidence of rare serious adverse events associated with the use of new
      and established OCs, and specifically the incidence of thromboembolic events.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Active surveillance using valid epidemiologic study designs is desirable for any new product,
      because adverse effects may occur that have not yet been identified in pre-marketing studies.

      The EURAS study investigates the safety of oral contraceptives with a large cohort of women
      attending offices of prescribing physicians. Its primary objective will be to compare
      incidence rates of adverse events in users of so-called new OCs and users of other OCs. The
      study is conducted as a phase IV commitment to the European Drug Authorities.

      The combined cohort will include 50,000 to 60,000 women recruited by a selected set of
      physicians in six European countries. A total of more than 1,500,000 cycles are expected to
      be observed during the field work which will start early in 2001 and end early in 2006.

      The participating women will undergo a baseline survey using a self administered
      questionnaire to describe the baseline risk. Every six months they will fill out a
      questionnaire in which they will record complaints and events during the use of the
      prescribed OC which will be validated. A multifaceted 4-level follow-up procedure will be
      established to ensure low loss to follow-up rates.

      Based on experience obtained in previous OC studies complex sources of bias and confounding
      are expected. Thus, multivariate methods such as Cox regression will be used to adjust for
      confounding. Regarding the impact of the results on public health, the main emphasis will be
      on the absolute risk estimates.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2000</start_date>
  <completion_date>December 2005</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Venous Thromboembolism (VTE)</measure>
    <time_frame>1.5 to 5 years</time_frame>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">59510</enrollment>
  <condition>Contraception</condition>
  <arm_group>
    <arm_group_label>Users of Drospirenone (DRSP)</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Users of Levonorgestrel (LNG)</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Users of other oral contraceptives (OCs)</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drospirenone</intervention_name>
    <arm_group_label>Users of Drospirenone (DRSP)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levonorgestrel</intervention_name>
    <arm_group_label>Users of Levonorgestrel (LNG)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Other progestin containing oral contraceptive</intervention_name>
    <arm_group_label>Users of other oral contraceptives (OCs)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Women prescribed hormonal contraceptives
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women starting OC use or women switching OCs

          -  Women willing to participate in the active surveillance for several years

        Exclusion Criteria:

          -  Women who have contraindications for OC use
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juergen C Dinger, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center for Epidemiology and Health Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for Epidemiology and Health Research</name>
      <address>
        <city>Berlin</city>
        <zip>10115</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <results_reference>
    <citation>Heinemann LA, Dinger J. Safety of a new oral contraceptive containing drospirenone. Drug Saf. 2004;27(13):1001-18. Review.</citation>
    <PMID>15471507</PMID>
  </results_reference>
  <results_reference>
    <citation>Dinger JC, Heinemann LA, KÃ¼hl-Habich D. The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation. Contraception. 2007 May;75(5):344-54. Epub 2007 Feb 23.</citation>
    <PMID>17434015</PMID>
  </results_reference>
  <verification_date>November 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 13, 2006</study_first_submitted>
  <study_first_submitted_qc>March 13, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 15, 2006</study_first_posted>
  <results_first_submitted>June 23, 2009</results_first_submitted>
  <results_first_submitted_qc>November 6, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 20, 2009</results_first_posted>
  <last_update_submitted>November 6, 2009</last_update_submitted>
  <last_update_submitted_qc>November 6, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 20, 2009</last_update_posted>
  <responsible_party>
    <name_title>Juergen Dinger, MD, PhD, Principal Investigator</name_title>
    <organization>Berlin Center for Epidemiology and Health Research, Germany</organization>
  </responsible_party>
  <keyword>Venous thromboembolism</keyword>
  <keyword>Drospirenone</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Levonorgestrel</mesh_term>
    <mesh_term>Contraceptives, Oral</mesh_term>
    <mesh_term>Drospirenone</mesh_term>
    <mesh_term>Progestins</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 59510 women were enrolled. Thereof 836 were excluded as they did not sign the informed consent form, were enrolled two or more times, continued their old OC or did not start OC use. In addition 371 used non oral hormonal contraception at study entry. These women were only used for the comparison of baseline risks.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Users of Drospirenone (DRSP)</title>
          <description>Women who use oral contraceptives (OCs) containing DRSP as progestin</description>
        </group>
        <group group_id="P2">
          <title>Users of Levonorgestrel (LNG)</title>
          <description>Women who use oral contraceptives (OCs) containing LNG as progestin</description>
        </group>
        <group group_id="P3">
          <title>Users of Other Oral Contraceptives (OCs)</title>
          <description>Women who use oral contraceptives (OCs) containing other progestins</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16534"/>
                <participants group_id="P2" count="15428"/>
                <participants group_id="P3" count="26341"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16133">Numbers completed refer to first follow-up. Individual follow-up ranged between 1.5 and 5.0 years.</participants>
                <participants group_id="P2" count="15009">Numbers completed refer to first follow-up. Individual follow-up ranged between 1.5 and 5.0 years.</participants>
                <participants group_id="P3" count="25762">Numbers completed refer to first follow-up. Individual follow-up ranged between 1.5 and 5.0 years.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="401"/>
                <participants group_id="P2" count="419"/>
                <participants group_id="P3" count="579"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Users of Drospirenone (DRSP)</title>
          <description>Women who use oral contraceptives (OCs) containing DRSP as progestin</description>
        </group>
        <group group_id="B2">
          <title>Users of Levonorgestrel (LNG)</title>
          <description>Women who use oral contraceptives (OCs) containing LNG as progestin</description>
        </group>
        <group group_id="B3">
          <title>Users of Other Oral Contraceptives (OCs)</title>
          <description>Women who use oral contraceptives (OCs) containing other progestins</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16534"/>
            <count group_id="B2" value="15428"/>
            <count group_id="B3" value="26341"/>
            <count group_id="B4" value="58303"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3,454"/>
                    <measurement group_id="B2" value="4,215"/>
                    <measurement group_id="B3" value="6,307"/>
                    <measurement group_id="B4" value="13976"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13,080"/>
                    <measurement group_id="B2" value="11,213"/>
                    <measurement group_id="B3" value="20,034"/>
                    <measurement group_id="B4" value="44327"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.9" spread="8.1"/>
                    <measurement group_id="B2" value="25.1" spread="8.7"/>
                    <measurement group_id="B3" value="24.8" spread="7.8"/>
                    <measurement group_id="B4" value="25.2" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16,534"/>
                    <measurement group_id="B2" value="15,428"/>
                    <measurement group_id="B3" value="26,341"/>
                    <measurement group_id="B4" value="58303"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Europe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16,534"/>
                    <measurement group_id="B2" value="15,428"/>
                    <measurement group_id="B3" value="26,341"/>
                    <measurement group_id="B4" value="58303"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Venous Thromboembolism (VTE)</title>
        <time_frame>1.5 to 5 years</time_frame>
        <population>The primary analysis compares the users of DRSP and LNG. Its results are presented below. The comparison of users of DRSP and OCs containing other progestins was only conducted for exploratory reasons. This secondary analysis showed similar results and is described in more detail in the publication of study results, see &quot;citations&quot;.</population>
        <group_list>
          <group group_id="O1">
            <title>Users of DRSP</title>
            <description>Women who use authorized oral contraceptives containing DRSP prescribed by their gynecologist</description>
          </group>
          <group group_id="O2">
            <title>Users of LNG</title>
            <description>Women who use authorized oral contraceptives containing LNG prescribed by their gynecologist</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Venous Thromboembolism (VTE)</title>
          <population>The primary analysis compares the users of DRSP and LNG. Its results are presented below. The comparison of users of DRSP and OCs containing other progestins was only conducted for exploratory reasons. This secondary analysis showed similar results and is described in more detail in the publication of study results, see &quot;citations&quot;.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16534"/>
                <count group_id="O2" value="15428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: HR â¥ 2 (VTE of DRSP vs. LNG)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Sample size calculations for VTE risk showed that 50,000 patients should be sufficient to exclude a twofold risk.</non_inferiority_desc>
            <p_value>&lt;0.05</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.6</ci_lower_limit>
            <ci_upper_limit>1.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Between 1.5 and 5 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Users of Drospirenone (DRSP)</title>
          <description>Women who use oral contraceptives (OCs) containing DRSP as progestin</description>
        </group>
        <group group_id="E2">
          <title>Users of Levonorgestrel (LNG)</title>
          <description>Women who use oral contraceptives (OCs) containing LNG as progestin</description>
        </group>
        <group group_id="E3">
          <title>Users of Other Oral Contraceptives (OCs)</title>
          <description>Women who use oral contraceptives (OCs) containing other progestins</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="965" subjects_at_risk="16534"/>
                <counts group_id="E2" subjects_affected="1059" subjects_at_risk="15428"/>
                <counts group_id="E3" subjects_affected="1815" subjects_at_risk="26341"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Diseases of the blood and blood-forming organs</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="16534"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="15428"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="26341"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiovascular diseases</sub_title>
                <counts group_id="E1" subjects_affected="91" subjects_at_risk="16534"/>
                <counts group_id="E2" subjects_affected="99" subjects_at_risk="15428"/>
                <counts group_id="E3" subjects_affected="171" subjects_at_risk="26341"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Endocrine diseases</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="16534"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="15428"/>
                <counts group_id="E3" subjects_affected="55" subjects_at_risk="26341"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye diseases</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="16534"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="15428"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="26341"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Digestive diseases</sub_title>
                <counts group_id="E1" subjects_affected="121" subjects_at_risk="16534"/>
                <counts group_id="E2" subjects_affected="124" subjects_at_risk="15428"/>
                <counts group_id="E3" subjects_affected="195" subjects_at_risk="26341"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="16534"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="15428"/>
                <counts group_id="E3" subjects_affected="50" subjects_at_risk="26341"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infectious diseases</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="16534"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="15428"/>
                <counts group_id="E3" subjects_affected="82" subjects_at_risk="26341"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injuries</sub_title>
                <counts group_id="E1" subjects_affected="192" subjects_at_risk="16534"/>
                <counts group_id="E2" subjects_affected="207" subjects_at_risk="15428"/>
                <counts group_id="E3" subjects_affected="372" subjects_at_risk="26341"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Diseases of the musculoskeletal system</sub_title>
                <counts group_id="E1" subjects_affected="151" subjects_at_risk="16534"/>
                <counts group_id="E2" subjects_affected="162" subjects_at_risk="15428"/>
                <counts group_id="E3" subjects_affected="261" subjects_at_risk="26341"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Malignant neoplasms</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="16534"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="15428"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="26341"/>
              </event>
              <event>
                <sub_title>Benign neoplasms</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="16534"/>
                <counts group_id="E2" subjects_affected="64" subjects_at_risk="15428"/>
                <counts group_id="E3" subjects_affected="117" subjects_at_risk="26341"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychiatric and neurological diseases</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="16534"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="15428"/>
                <counts group_id="E3" subjects_affected="109" subjects_at_risk="26341"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Genitourinary diseases</sub_title>
                <counts group_id="E1" subjects_affected="91" subjects_at_risk="16534"/>
                <counts group_id="E2" subjects_affected="94" subjects_at_risk="15428"/>
                <counts group_id="E3" subjects_affected="178" subjects_at_risk="26341"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory diseases</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="16534"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="15428"/>
                <counts group_id="E3" subjects_affected="41" subjects_at_risk="26341"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin diseases</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="16534"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="15428"/>
                <counts group_id="E3" subjects_affected="120" subjects_at_risk="26341"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16534"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15428"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26341"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This is an observational study. The possibility of bias and residual confounding cannot be entirely eliminated.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Juergen Dinger, MD, PhD, Principal Investigator</name_or_title>
      <organization>Berlin Center for Epidemiology and Health Research, Germany</organization>
      <phone>+49 30 94510145</phone>
      <email>dinger@zeg-berlin.de</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

